See more : Boston Private Financial Holdings, Inc. (BPFH) Income Statement Analysis – Financial Results
Complete financial analysis of BioCardia, Inc. (BCDA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioCardia, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Maj Invest Value Aktier Akk (MAJVAA.CO) Income Statement Analysis – Financial Results
- Noritake Co., Limited (5331.T) Income Statement Analysis – Financial Results
- Rohto Pharmaceutical Co.,Ltd. (4527.T) Income Statement Analysis – Financial Results
- StartMonday Technology Corp. (STMDF) Income Statement Analysis – Financial Results
- Twentyfirst Century Management Services Limited (21STCENMGM.NS) Income Statement Analysis – Financial Results
BioCardia, Inc. (BCDA)
About BioCardia, Inc.
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 477.00K | 1.35M | 1.02M | 145.00K | 710.00K | 625.00K | 479.00K | 576.00K | 517.00K | 427.00K | 268.00K | 62.00K | 12.00K | 0.00 | 1.87M | 1.27M | 643.00K | 0.00 | 0.00 | 0.00 | 3.76M | 4.08M | 3.96M | 3.87M | 3.99M | 4.20M | 3.80M | 3.40M | 3.15M |
| Cost of Revenue | 7.73M | 11.90M | 640.00K | 4.00K | 358.00K | 517.00K | 690.00K | 746.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 380.00K | 197.00K | 130.00K | 0.00 | 0.00 | 0.00 | 860.33K | 1.01M | 971.26K | 952.26K | 898.17K | 1.00M | 900.00K | 800.00K | 727.61K |
| Gross Profit | -7.25M | -10.55M | 375.00K | 141.00K | 352.00K | 108.00K | -211.00K | -170.00K | 517.00K | 427.00K | 268.00K | 62.00K | 12.00K | 0.00 | 1.49M | 1.07M | 513.00K | 0.00 | 0.00 | 0.00 | 2.90M | 3.07M | 2.99M | 2.91M | 3.09M | 3.20M | 2.90M | 2.60M | 2.42M |
| Gross Profit Ratio | -1,519.71% | -780.25% | 36.95% | 97.24% | 49.58% | 17.28% | -44.05% | -29.51% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 79.67% | 84.46% | 79.78% | 0.00% | 0.00% | 0.00% | 77.12% | 75.32% | 75.46% | 75.37% | 77.48% | 76.19% | 76.32% | 76.47% | 76.89% |
| Research & Development | 7.73M | 8.83M | 8.56M | 9.81M | 8.56M | 8.45M | 5.80M | 3.33M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00M | 1.33M | 215.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.73M | 0.00 | 198.00K | 196.00K | 259.00K | 401.00K | 630.00K | 583.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.66M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.40M | 4.42M | 5.09M | 5.86M | 6.00M | 5.76M | 6.40M | 4.11M | 198.00K | 196.00K | 259.00K | 401.00K | 630.00K | 583.00K | 5.59M | 3.91M | 610.00K | 79.80K | 98.18K | 101.48K | 3.59M | 3.58M | 4.14M | 4.93M | 4.90M | 4.30M | 4.00M | 3.20M | 2.21M |
| Other Expenses | 0.00 | -6.00K | -2.00K | -2.00K | -2.00K | -3.00K | 2.00K | -2.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -5.37K | 0.00 | 85.72K | 0.00 | 0.00 | 0.00 | 115.45K | 100.00K | 100.00K | 100.00K | 0.00 |
| Operating Expenses | 12.12M | 13.25M | 13.65M | 15.67M | 14.57M | 14.21M | 12.19M | 7.44M | 198.00K | 196.00K | 259.00K | 401.00K | 630.00K | 583.00K | 6.59M | 5.25M | 825.00K | 79.80K | 92.80K | 101.48K | 3.68M | 3.58M | 4.14M | 4.93M | 5.02M | 4.40M | 4.10M | 3.30M | 2.21M |
| Cost & Expenses | 12.12M | 13.25M | 13.65M | 15.67M | 14.92M | 14.73M | 12.88M | 8.18M | 198.00K | 196.00K | 259.00K | 401.00K | 630.00K | 583.00K | 6.97M | 5.44M | 955.00K | 79.80K | 92.80K | 101.48K | 4.54M | 4.58M | 5.11M | 5.88M | 5.91M | 5.40M | 5.00M | 4.10M | 2.94M |
| Interest Income | 0.00 | 0.00 | 9.00K | 21.00K | 87.00K | 118.00K | 95.00K | 0.00 | 3.00K | 3.00K | 10.00K | 8.00K | 11.00K | 0.00 | 0.00 | 0.00 | 33.00K | 4.36K | 5.37K | 1.70K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 6.00K | 0.00 | 3.00K | 112.00K | 0.00 | 95.00K | 1.74M | 3.00K | 3.00K | 10.00K | 8.00K | 25.00K | 27.00K | 24.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 32.00K |
| Depreciation & Amortization | 84.00K | 377.00K | 640.00K | 566.00K | 551.00K | 203.00K | 78.00K | 39.00K | 0.00 | 0.00 | 0.00 | 0.00 | 11.00K | 967.00K | 1.21M | 561.00K | 61.00K | 0.00 | 0.00 | 0.00 | 71.08K | 84.93K | 101.83K | 107.91K | 115.45K | 100.00K | 100.00K | 100.00K | 49.74K |
| EBITDA | -11.56M | -11.82M | -12.57M | -14.44M | -14.05M | -13.90M | -12.23M | -8.54M | 319.00K | 231.00K | 9.00K | -339.00K | -618.00K | 384.00K | -3.90M | -3.61M | -218.00K | -79.80K | -92.80K | -101.48K | -99.79K | -443.03K | -418.80K | -1.05M | -1.91M | -1.81M | -1.10M | -1.00M | -600.00K |
| EBITDA Ratio | -2,423.48% | -880.25% | -1,237.73% | -10,649.66% | -1,974.23% | -2,223.84% | -2,573.49% | -1,146.70% | 61.70% | 54.10% | 3.36% | -546.77% | -5,058.33% | 0.00% | -208.40% | -170.11% | -33.90% | 0.00% | 0.00% | 0.00% | -18.08% | -10.86% | -24.66% | -50.88% | -54.95% | -23.81% | -42.11% | -17.65% | 9.25% |
| Operating Income | -11.64M | -11.90M | -12.63M | -15.53M | -14.21M | -14.10M | -12.41M | -7.61M | 319.00K | 231.00K | 9.00K | -339.00K | -618.00K | -583.00K | -5.10M | -5.63M | -312.00K | -79.80K | -92.80K | -101.48K | -779.68K | -503.74K | -1.15M | -2.02M | -1.93M | -1.20M | -1.20M | -700.00K | 206.23K |
| Operating Income Ratio | -2,441.09% | -880.25% | -1,244.33% | -10,709.66% | -2,001.83% | -2,256.32% | -2,589.77% | -1,320.83% | 61.70% | 54.10% | 3.36% | -546.77% | -5,150.00% | 0.00% | -272.98% | -444.16% | -48.52% | 0.00% | 0.00% | 0.00% | -20.74% | -12.35% | -29.13% | -52.20% | -48.28% | -28.57% | -31.58% | -20.59% | 6.55% |
| Total Other Income/Expenses | 73.00K | -6.00K | 7.00K | 525.00K | -496.00K | 115.00K | 97.00K | -2.70M | 3.00K | 3.00K | 10.00K | 8.00K | -14.00K | 27.00K | 24.00K | -20.00K | 33.00K | -199.20K | 0.00 | 0.00 | 679.90K | 24.23K | 24.23K | 56.84K | 56.84K | 625.51K | 500.00K | 0.00 | 839.12K |
| Income Before Tax | -11.57M | -11.91M | -12.62M | -15.00M | -14.71M | -13.99M | -12.31M | -10.31M | 322.00K | 234.00K | 19.00K | -331.00K | -632.00K | -556.00K | -5.08M | -5.80M | -279.00K | 0.00 | 0.00 | 0.00 | -722.70K | -479.51K | -1.23M | -1.96M | -1.54M | -1.30M | -700.00K | 0.00 | 139.12K |
| Income Before Tax Ratio | -2,425.79% | -880.70% | -1,243.65% | -10,347.59% | -2,071.69% | -2,237.92% | -2,569.52% | -1,789.93% | 62.28% | 54.80% | 7.09% | -533.87% | -5,266.67% | 0.00% | -271.70% | -457.41% | -43.39% | 0.00% | 0.00% | 0.00% | -19.22% | -11.76% | -31.02% | -50.73% | -38.72% | -30.95% | -18.42% | 0.00% | 4.42% |
| Income Tax Expense | 0.00 | 6.00K | -2.00K | 1.00K | 110.00K | -115.00K | -192.00K | 5.40M | -6.00K | -6.00K | -20.00K | -652.00K | -10.31M | 10.90M | -48.00K | 3.10M | 0.00 | -4.36K | 92.80K | 710.86K | -28.24K | -48.45K | 149.87K | 103.91K | -762.83K | 200.00K | -1.10M | -100.00K | 3.53K |
| Net Income | -11.57M | -11.91M | -12.62M | -15.01M | -14.82M | -13.87M | -12.31M | -10.31M | 322.00K | 234.00K | 19.00K | 305.00K | 9.66M | -11.51M | -5.08M | -5.80M | -287.00K | -75.44K | -92.80K | -812.34K | -722.70K | -479.51K | -1.23M | -2.18M | -1.54M | -1.30M | -600.00K | -600.00K | 135.60K |
| Net Income Ratio | -2,425.79% | -881.14% | -1,243.45% | -10,348.28% | -2,087.18% | -2,219.52% | -2,569.52% | -1,789.93% | 62.28% | 54.80% | 7.09% | 491.94% | 80,516.67% | 0.00% | -271.70% | -457.41% | -44.63% | 0.00% | 0.00% | 0.00% | -19.22% | -11.76% | -31.02% | -56.35% | -38.72% | -30.95% | -15.79% | -17.65% | 4.31% |
| EPS | -8.19 | -10.08 | -11.19 | -22.24 | -39.38 | -48.80 | -43.54 | -166.33 | 27.86 | 20.50 | 1.78 | 28.61 | 906.29 | -1.08K | -528.72 | -742.35 | -34.84 | -8.21 | -10.10 | -98.42 | -92.38 | -61.30 | -156.91 | -275.16 | -237.12 | -210.36 | -97.17 | -117.32 | 0.38 |
| EPS Diluted | -8.19 | -10.08 | -11.19 | -22.24 | -39.38 | -48.80 | -43.54 | -166.33 | 27.86 | 20.50 | 1.78 | 28.61 | 906.29 | -1.08K | -528.72 | -742.35 | -34.84 | -8.21 | -10.10 | -98.42 | -92.38 | -61.30 | -156.15 | -275.16 | -237.12 | -204.63 | -97.17 | -113.64 | 0.38 |
| Weighted Avg Shares Out | 1.41M | 1.18M | 1.13M | 674.58K | 376.29K | 284.28K | 282.67K | 61.99K | 11.56K | 11.41K | 10.66K | 10.66K | 10.66K | 10.66K | 9.60K | 7.81K | 8.24K | 9.19K | 9.19K | 8.25K | 7.82K | 7.82K | 7.82K | 7.92K | 6.51K | 6.18K | 6.18K | 5.11K | 360.60K |
| Weighted Avg Shares Out (Dil) | 1.41M | 1.18M | 1.13M | 674.58K | 376.29K | 284.28K | 282.67K | 61.99K | 11.56K | 11.41K | 10.66K | 10.66K | 10.66K | 10.66K | 9.60K | 7.81K | 8.24K | 9.19K | 9.19K | 8.25K | 7.82K | 7.82K | 7.86K | 7.92K | 6.51K | 6.35K | 6.18K | 5.28K | 360.60K |
BioCardia Announces FDA Approval of Its IND for NK1R+ Mesenchymal Stem Cells for the Treatment of Patients Recovering from Acute Respiratory Distress due to COVID-19
Phase I/II trial initiation expected in 3Q 2022 Phase I/II trial initiation expected in 3Q 2022
BioCardia, Inc. (BCDA) CEO Peter Altman on Q4 2021 Results - Earnings Call Transcript
BioCardia, Inc. (BCDA) CEO Peter Altman on Q4 2021 Results - Earnings Call Transcript
BioCardia Reports 2021 Financial Results and Recent Business Highlights
SUNNYVALE, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended December 31, 2021 and filed its...
BioCardia to Host 2021 Financial Results and Corporate Update Conference Call on March 29, 2022
SUNNYVALE, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the year ended December 31,...
BioCardia Announces New Center for Medicare and Medicaid Services Reimbursement Code Applicable to the CardiAMP Cell Therapy Procedure
New Procedure Reimbursement Code Expected to Enhance Study Performance for Clinical Centers Participating in the CardiAMP Cell Therapy Heart Failure Trial and the CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial New Procedure Reimbursement Code Expected to Enhance Study Performance for...
BioCardia Receives No Objection Letter from Health Canada, Enabling Company to Expand CardiAMP Cell Therapy Heart Failure Trial into Canada
SUNNYVALE, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has received a No Objection Letter from Health Canada, the...
Safety Board Recommends BioCardia's Heart Failure Cell Therapy To Continue Unchanged
The independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for BioCardia Inc's (NASDAQ: BCDA) ongoing Phase 3 CardiAMP Cell Therapy Heart Failure Trial. The DSMB based its review on all available data for the 108 patients enrolled with an additional...
BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Study as Designed
SUNNYVALE, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announces that the independent Data Safety Monitoring Board (DSMB) has completed its...
Why Are BioCardia Shares Trading Higher Today?
The FDA has granted Breakthrough Device Designation for BioCardia Inc's BCDA CardiAMP Cell Therapy System to treat heart failure. Get the Inside Access Traders Are Using to Profit More and Win Bigger.
BioCardia Receives FDA Breakthrough Device Designation for CardiAMP Cell Therapy System for Heart Failure
SUNNYVALE, Calif.--(BUSINESS WIRE)--BioCardia®, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the CardiAMP® Cell...
Source: https://incomestatements.info
Category: Stock Reports